Best CDMOs in South Korea — Ranked by Signal Score · 2026

Last updated: 2026-08-31 · updated as new inspection, certificate, and trial data enters the platform

USA Europe Asia UK India Switzerland Germany South Korea Japan China

CDMOs in region

Fully scored

With FDA records

FDA inspections

EMA/MHRA GMP certs

CDMO Signal tracks 9 biopharma CDMOs with confirmed South Korea manufacturing facilities, of which 7 are fully scored across the four-pillar composite Signal Score. Across all modalities, Lotte Biologics, SK pharmteco, and ST Pharm lead the South Korea ranking by composite score. Signal Score integrates FDA inspection history, EMA/MHRA GMP certificate density, ClinicalTrials.gov sponsor footprint, and monitored capacity signals. For modality-specific rankings within South Korea — AAV, cell therapy, biologics, and 10 other tracked modalities — see the modality-region breakdown below. Full methodology at cdmosignal.com/methodology.

South Korea-based CDMOs ranked by CDMO Signal's composite Signal Score, filtered to manufacturers with confirmed Korean facilities. South Korea's biologics CDMO sector — led by Samsung Biologics and Celltrion — is one of the most rapidly growing globally, with substantial commercial-scale mammalian cell culture capacity and increasing FDA + EMA inspection posture. This ranking includes any CDMO with a South Korean manufacturing site.

#	CDMO	Signal Score	Quality	FDA · GMP	Capacity	Programs
1	LB Lotte Biologics Incheon, KR · Syracuse, NY	83.7	100.0	1 insp · 0 GMP	—	0 programs
2	SK SK pharmteco Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.	79.5	100.0	—	Available	0 programs
3	SP ST Pharm Seoul, South Korea	72.8	88.1	2 insp · 4 GMP	—	0 programs
4	SB Samsung Biologics Incheon, South Korea, Rockville, Maryland, USA	61.5	—	—	Available	0 programs
5	HX Helixmith Seoul, KR	59.0	—	—	—	0 programs
6	GC Green Cross Cell Yongin, KR	56.5	—	—	—	0 programs
7	CH CHA Medical & Bio Group Seongnam, KR	56.5	—	—	—	0 programs
—	Novelty Nobility Inc. Seoul, South Korea	Profiled	—	—	—	0 programs
—	CdmoGen Co., Ltd. Cheongju, South Korea	Profiled	—	—	—	0 programs

How we score CDMOs →

What has driven South Korea's rise as a biologics manufacturing hub?

South Korea's biologics CDMO growth (2015-present) has been driven by three factors: (1) Samsung Biologics' massive Songdo capacity build (Plants 1-5 total >600,000L mammalian cell culture, one of the largest single-city concentrations of biologics capacity globally); (2) Celltrion's biosimilar-driven commercial capacity, exported globally; (3) national policy focus on biopharmaceutical export as a strategic industry. Korean CDMOs supplying US and EU markets typically hold MFDS + FDA + EMA certifications concurrently — the Signal Score's Quality Compliance pillar captures all three. For biologics programs specifically, South Korea offers commercial-scale capacity availability that is genuinely scarce in the US and EU.

How do Samsung Biologics and Celltrion compare on CDMO offerings?

Samsung Biologics operates primarily as a contract manufacturer (CDMO) with dedicated commercial biologics capacity at Songdo; Celltrion combines internal biosimilar development with CDMO services, with significant capacity dedicated to their own commercial products. For pure CDMO engagements, Samsung Biologics is typically the more scale-available option; for programs where biosimilar development experience is a plus, Celltrion's integrated model can add value. Both hold FDA and EMA certifications. Cross-check with the biologics CDMO ranking for the broader Korean biologics landscape and individual profile pages for facility-level detail.

South Korean CDMOs supplying US and EU markets — regulatory considerations

South Korean CDMOs supplying US and EU markets need active FDA and EMA GMP certifications on the specific facility. Both regulators have inspection experience with major Korean biologics sites, and inspection outcomes have generally been favorable. For programs supplying UK specifically, post-Brexit MHRA acceptance of MFDS + EMA-recognized inspections has continued under transitional arrangements — sponsors should confirm current MHRA policy at RFP stage. The Signal Score's Quality Compliance pillar captures FDA + EMA + MHRA data directly, so Korean CDMOs with cross-jurisdictional posture rank higher on this pillar than domestic-market-only competitors.

Browse by modality within South Korea

Modality-specific rankings for South Korea-manufactured programs. Each page filters the modality's global ranking to CDMOs with confirmed South Korea facilities.

AAV / Gene Therapy (4) Lentiviral Vector (2) Cell Therapy (4) mRNA / LNP (3) Plasmid DNA (2) Biologics / mAb (1) Oligonucleotide / ASO (1) Adenoviral Vector (1) Recombinant Proteins (1) ADC (Antibody-Drug Conjugate) (3) Gene Therapy (4) Cell & Gene Therapy (6) Viral Vector (4)

Other regions

CDMOs in United States CDMOs in Europe CDMOs in Asia CDMOs in United Kingdom CDMOs in India CDMOs in Switzerland CDMOs in Germany CDMOs in Japan CDMOs in China